SCHEMBL2013192

SCHEMBL2013192

Cc1cc(N)ncc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 6/20 1.00
GABRD O14764 6/20 1.00
GABRA1 P14867 6/20 1.00
GABRB1 P18505 6/20 1.00
GABRG2 P18507 6/20 1.00
GABRB3 P28472 6/20 1.00
GABRA5 P31644 6/20 1.00
GABRA3 P34903 6/20 1.00
GABRA2 P47869 6/20 1.00
GABRB2 P47870 6/20 1.00
GABRA4 P48169 6/20 1.00
GABRE P78334 6/20 1.00
GABRA6 Q16445 6/20 1.00
GABRG1 Q8N1C3 6/20 1.00
GABRG3 Q99928 6/20 1.00
GABRQ Q9UN88 6/20 1.00
KDM4E B2RXH2 5/20 0.55
KMT2A Q03164 2/20 0.55
LDHA P00338 1/20 0.54
NOS3 P29474 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20640895 0.84 GABRP (0.72) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL19414812 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2012842 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1436086 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31043801 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5336718 0.78 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL19857491 0.78 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9508554 0.78 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5356192 0.78 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2859500 0.77 GABRP (1.00) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115537783-A Preparation process of metal surface laser strengthening coating 苏州酷咔智能科技有限公司 2022-12-30 CN claimed
WO-2003013523-A1 SH3 PROTEIN DOMAINS AND THEIR LIGANDS ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) 2003-02-20 WO claimed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 US claimed
WO-1996018616-A1 SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-06-20 WO claimed
CN-122036587-A Zalutst compound and application thereof in inhibiting MLL1-WDR5 interaction 暨南大学 2026-05-15 CN disclosed
US-12472181-B2 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (BE) 2025-11-18 US disclosed
CN-117534670-A Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders 加拉帕戈斯股份有限公司 2024-02-09 CN disclosed
EP-3697784-B9 IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2023-12-27 EP disclosed
CN-111225916-B Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders 加拉帕戈斯股份有限公司 2023-11-03 CN disclosed
EP-4265254-A2 IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Galapagos N.V. (BE) 2023-10-25 EP disclosed
EP-4265254-A2 IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Galapagos N.V. (BE) 2023-10-25 EP disclosed
US-20230310433-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2023-10-05 US disclosed
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 NOVARTIS AG (CH) 2013-06-13 US disclosed
CN-102918043-A Pyrrolopyrimidine compounds as CDK4/6 inhibitors NOVARTIS AG 2013-02-06 CN disclosed
WO-2011073316-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2011-06-23 WO disclosed
WO-2011073316-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2011-06-23 WO disclosed
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them WARNER-LAMBERT COMPANY LLC 2004-04-15 US disclosed
WO-2003013523-A1 SH3 PROTEIN DOMAINS AND THEIR LIGANDS ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) 2003-02-20 WO disclosed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 US disclosed
WO-1996018616-A1 SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 CDK4, CDK6, CCNT1 GABRP 4691/4885GABRD 4462/4885GABRA1 4776/4885
US-20040072871-A1 Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them MMP11, MMP13, CBR1 GABRP 1296/4885GABRD 1504/4885GABRA1 1699/4885
US-20230310433-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS IL15, IL2, IL33 GABRP 3439/4885GABRD 4287/4885GABRA1 3628/4885
US-12472181-B2 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders IL15, IL2, IL33 GABRP 3439/4885GABRD 4287/4885GABRA1 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.